We report a 10-year-old male with widespread recurrent Burkitt's lymphoma who underwent successful mismatched unrelated cord blood transplantation (UCBT) following salvage chemotherapy. He was conditioned with TBI, antithymocyte globulin (ATG) and high-dose VP-16 and achieved full donor engraftment. He experienced grade II skin and grade I gastrointestinal acute GVHD with no chronic GVHD. He is alive with no evidence of disease 24 months following UCBT. Bone Marrow Transplantation (2000) 25, 1311-1313. Keywords: Burkitt's lymphoma; cord blood transplant; graft-versus-lymphoma Non-Hodgkin's lymphoma (NHL) is the third most common pediatric malignancy. In contrast to adults, over 90% of pediatric NHL is high-grade pathology with Burkitt's lymphoma comprising 35% of pediatric NHL.
Non-Hodgkin's lymphoma (NHL) is the third most common pediatric malignancy. In contrast to adults, over 90% of pediatric NHL is high-grade pathology with Burkitt's lymphoma comprising 35% of pediatric NHL. 1 Short intensive chemotherapy regimens with modern supportive care have produced cure rates of 85-95% in stage I and II patients, as well as 75-85% in advanced stage patients. 1 However, the prognosis for relapsed Burkitt's NHL is extremely poor. Salvage high-dose chemotherapy regimens with autologous stem cell transplant consolidation have yielded unsatisfactory results with less than 40% long-term survival.
1,2 Allogeneic transplant results in NHL have suggested a GVL effect, but have been associated with increased toxicity. [3] [4] [5] [6] We now report a successful UCBT in a child with relapsed Burkitt's lymphoma with disease in his abdomen and bone marrow (BM). This case suggests that UCBT can be used to successfully maintain a long-term remission and cure in this high risk setting.
Case report
A 10-year-old male was diagnosed with Murphy stage II abdominal Burkitt's lymphoma in November 1997 after The patient was treated again in February 1998 with intensive LMB-89 chemotherapy including high-dose methotrexate, cyclophosphamide, prednisone and adriamycin, as well as intrathecal triple medications with hydrocortisone, methotrexate, and cytosine arabinoside. He developed significant tumor lysis syndrome, mucositis, and neutropenic fever, but recovered without sequelae. He then received a second course of reinduction therapy in March 1998 utilizing ifosfamide, VP-16, and high-dose cytosine arabinoside.
The patient achieved an excellent clinical response after these two cycles of chemotherapy. He had no HLA-identical sibling and no acceptable unrelated marrow donors were identified. A 5/6 HLA-matched (DR locus mismatch) umbilical cord stem cell unit was identified in the Dusseldorf, Germany Cord Blood Bank. The cord characteristics are shown in Table 1 .
The patient underwent conditioning for his UCBT after informed consent was obtained according to institutional protocol. His conditioning regimen consisted of TBI (1350 cGy in nine fractions) from day −8 to −4, VP-16 (60 mg/kg) day −3, and ATG (20 mg/kg) on days −6, −4, −2. He also received additional cranial radiation (450 cGy in three fractions) immediately prior to initiating conditioning. He received the cord blood infusion on 13 April 1998. GVHD prophylaxis consisted of CsA, prednisone, and ATG (given every other day from day 5 until day 19).
He reached an ANC Ͼ0.5 × 10 9 /l on day +44, and
Bone Marrow Transplantation /l on day +105. His engraftment was 100% donor by XY FISH analysis of 300 cells on day +45. His post-transplant course has been remarkable only for several episodes of sinusitis and otitis media as well as an episode of varicella zoster, all of which were successfully treated with appropriate anti-infective medications.
His post-transplant radiographic evaluation demonstrates no evidence of disease as shown in Figure 2a 
Discussion
To our knowledge this is the first report of a successful UCBT for relapsed Burkitt's lymphoma. Umbilical cord blood has been increasingly used as a source of stem cells for transplantation since the initial report of success in 1988. Gluckman et al 7 reported a 29% 1 year survival rate with a 14% relapse rate in 65 European patients undergoing UCBT. Similarly, Rubinstein et al 8 reported a 100-day survival of 61% and a 14% relapse rate among 562 UCBT patients. These two large reports included a few cases of unspecified lymphoma with the New York group reporting a relapse rate of 15% in their 13 lymphoma cases.
Several reports have compared allogeneic BMT to autologous BMT in NHL, but not specifically in the Burkitt subtype. Bureo et al 5 reported a 58% 5-year EFS in 46 pediatric patients with no difference by stem cell source. Conversely, an adult NHL study reported a 47% (allo) vs 24% (auto) 1 year EFS in a group of 66 patients. 6 This suggestion of a positive GVL effect is supported by the high relapse rates in most autologous transplant NHL series. In vitro and in vivo models of cord blood transplantation have demonstrated the presence of biologically significant GVL via NK and LAK cell activity independent of T cell-mediated GVHD. 9 This may explain the relatively low relapse rate reported in UCBT despite the low incidence of significant GVHD in the setting of HLA-mismatched grafts. 7, 8, 10 Cord blood has been demonstrated to induce less GVHD and allow for more HLA disparity. 7, 8, 10 These properties, combined with an intensified conditioning regimen, may allow for grafts in older patients. We have recently engrafted a 55 kg and 75 kg recipient with the same UCBT protocol.
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Our patient is now 2 years after his UCBT with no evidence of disease and no GVHD. He is currently on no medication and has resumed all activities without any limitation. Future prospective studies should evaluate UCBT in relapsed lymphoma where autologous stem cell procedures have high relapse rates and GVL may be beneficial.
